Dedicated to significantly improving the health and well-being of patients affected by obesity and complex metabolic disorders


Zafgen (Nasdaq:ZFGN) is a biopharmaceutical company dedicated to significantly improving the health and well-being of patients affected by obesity and complex metabolic disorders. Zafgen is focused on developing novel therapeutics that treat the underlying biological mechanisms of severe and complicated obesity through the MetAP2 pathway. Zafgen has pioneered the study of MetAP2 inhibitors in both common and rare forms of obesity. Zafgen's lead product candidate is ZGN-1061, which is a novel, first-in-class, twice-weekly subcutaneous injection. Zafgen is also developing ZGN-839, a liver-targeted MetAP2 inhibitor, for the treatment of nonalcoholic steatohepatitis, or NASH, and abdominal obesity. Zafgen aspires to improve the lives of patients through targeted treatments and has assembled a team accomplished in bringing therapies to patients affected by metabolic diseases.


Year Invested: 2007
Location: Cambridge, Mass.
Visit: www.zafgen.com

Recent News

May 9, 2017
Zafgen Reports First Quarter 2017 Financial Results

May 4, 2017
Zafgen Announces Positive Topline Phase 1 Data for ZGN-1061, a Second Generation MetAP2 Inhibitor

March 9, 2017
Zafgen Reports Fourth Quarter and Full Year 2016 Financial Results

Read More News

Associated Team Members

Kevin Starr
Partner